FDA Inspection 1284298 — Roswell Park Cancer Institute Corporation. Div. Of Pathology
The FDA completed an inspection of Roswell Park Cancer Institute Corporation. Div. Of Pathology on Sep 19, 2025 in Buffalo, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 19, 2025
- Fiscal Year
- 2025
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Buffalo, NY (United States)